Repair Biotechnologies Closes Seed Round, Joins Incubator

I had promised a short update on progress at Repair Biotechnologies, the company that Bill Cherman and I founded earlier this year to help advance the state of therapies to treat aging, and here it is. We recently closed a seed round with a number of investors in our close-knit community, and are presently setting up our modest headquarters near Syracuse, NY, alongside our allies at Ichor Therapeutics. The staff at Ichor, fresh from a sizable investment made by Juvenescence in their subsidiary Antoxerene, have launched an incubator,, to encourage the development of new companies focused on the treatment of aging. Repair Biotechnologies is the first such company to be accepted to the program.

Our initial development program at Repair Biotechnologies progresses, and I'm pleased to be able to say that we have made our first scientific hire. We were fortunate to near immediately connect with a very talented protein biochemist in Syracuse, who will be joining us later this month. We continue to interview in search of another entrepreneurial scientist, someone with a cell biology and gene therapy background. If you know of scientists with an interest in aging and the talent to make a difference, please do point them in our direction.

Repair Biotechnologies, Inc., a startup developing therapies with the goals of reversing atherosclerosis and atrophy of the thymus, is proud to announce it has raised a seed round from leading institutions and angel investors in the growing longevity science community, including Methuselah Foundation and others.

Founded by Reason and Bill Cherman in April 2018, Repair Biotechnologies will use these new funds to expand its foundational gene therapy development work with the addition of a recombinant protein engineering program, as it proceeds towards proof of concept results in animal models.

Additionally, Repair Biotechnologies is pleased to announce that the company has been accepted to the incubator, recently launched by Ichor Therapeutics. The company is relocating to Upstate New York, to work hand in hand with the Ichor team towards the success of the Repair Biotechnologies development programs. Repair Biotechnologies is now hiring scientists for several positions in Lafayette, NY, just outside Syracuse.

"At Repair Biotechnologies, we are committed to developing treatments for aging and age-related diseases that address the root causes of these conditions. We are grateful for the financial support from top investors in our community, and look forward to working together with our friends at Ichor Therapeutics. We intend to draw upon their considerable experience in the field, and learn from their demonstrable success in structuring and executing challenging development programs," said Reason, CEO.

Nothing in this post should be construed as an offer to sell, or a solicitation of an offer to buy, any security or investment product. Certain information contained herein may contains statements, estimates and projections that are "forward-looking statements." All statements other than statements of historical fact in this post are forward-looking statements and include statements and assumptions relating to: plans and objectives of Repair Biotechnologies' management for future operations or economic performance; conclusions and projections about current and future economic and political trends and conditions; and projected financial results and results of operations. These statements can generally be identified by the use of forward-looking terminology including "may," "believe," "will," "expect," "anticipate," "estimate," "continue", "rankings" or other similar words. Repair Biotechnologies does not make any representations or warranties (express or implied) about the accuracy of such forward-looking statements. Accordingly, you should not place reliance on any forward-looking statements.


I am looking forward for the results :)

Btw, what is your target for funding and when do you think you will be able to have stage I product?

I guess that you will have less time for the website and many of your articles will have to have a lengthy legalese disclaimers. Do you plan of delegating the website work to somebody ?

Posted by: cuberat at August 10th, 2018 2:30 PM

@cuberat: I visit the site everyday.

Posted by: Gekki at August 10th, 2018 3:19 PM

@cuberat: I'll be able to keep up with Fight Aging! I won't be mentioning Repair Biotechnologies all that often here; there's a whole field to talk about, and my newer efforts are but one small part of the bigger tapestry.

Ultimately I'd like to see more sites similar to Fight Aging! spring up; that seems to be happening to some degree in the past few years. The LEAF folk are doing a good job with their blog, and a couple of other sites are publishing commentaries on at least a semi-regular basis.

Posted by: Reason at August 10th, 2018 3:30 PM

Congratulations :) Good to see that it's going well!

Posted by: Antonio at August 10th, 2018 5:40 PM

Given that genetically engineering cells ex-vivo appears to have just recently gotten much cheaper, easier, and more powerful (see T Cell Engineering Breakthrough Sidesteps Need for Viruses in CRISPR Gene-Editing) I hope you don't "run into the sand" when trying to genetically engineer macrophages with enzymes to break down oxidised cholesterol.

The possibilities of cheaper ex-vivo engineering combined with synnotch are endless. Imagine if once oxdisied cholesterol eating macrophages have been created, you could instead engineer marcrophages with synnotch receptors to proteins engineered on CAR T cells to turn off the macrophages response to the CD47 don't eat me signal only in the tumor micro environment.

Posted by: Jim at August 10th, 2018 11:18 PM


Glad you'll be able to keep up with the site. This is the first site I go to every day.

Gives me hope!

Posted by: bmack500 at August 13th, 2018 7:49 AM
Comment Submission

Post a comment; thoughtful, considered opinions are valued. New comments can be edited for a few minutes following submission. Comments incorporating ad hominem attacks, advertising, and other forms of inappropriate behavior are likely to be deleted.

Note that there is a comment feed for those who like to keep up with conversations.